Supplementary Figure S5 from Targeting the Clear Cell Sarcoma Oncogenic Driver Fusion Gene EWSR1::ATF1 by HDAC Inhibition

Mae, Hirokazu; Outani, Hidetatsu; Imura, Yoshinori; Chijimatsu, Ryota; Inoue, Akitomo; Kotani, Yuki; Yasuda, Naohiro; Nakai, Sho; Nakai, Takaaki; Takenaka, Satoshi; Okada, Seiji

doi:10.1158/2767-9764.23618559.v1

Supplementary Figure S5 from Targeting the Clear Cell Sarcoma Oncogenic Driver Fusion Gene <i>EWSR1::ATF1</i> by HDAC Inhibition

journal contribution

posted on 2023-07-03, 14:20 authored by Hirokazu Mae, Hidetatsu Outani, Yoshinori Imura, Ryota Chijimatsu, Akitomo Inoue, Yuki Kotani, Naohiro Yasuda, Sho Nakai, Takaaki Nakai, Satoshi Takenaka, Seiji Okada

<p>Fig. S5 A combination of vorinostat and mivebresib is effective for CCS</p>

Funding

MEXT | Japan Society for the Promotion of Science (JSPS)

Osaka Medical Research Foundation for Intractable Diseases

History

Related Materials

1.
DOI - Is supplement to Targeting the Clear Cell Sarcoma Oncogenic Driver Fusion Gene EWSR1::ATF1 by HDAC Inhibition

ARTICLE ABSTRACT

This study reveals the epigenetic and transcriptional suppression mechanism of the fusion oncogene EWSR1::ATF1 in clear cell sarcoma by histone deacetylase inhibitor treatment as well as identifying SOX10 as a transcription factor that regulates EWSR1::ATF1 expression.